Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
89.47
+2.06 (2.36%)
At close: Dec 5, 2025, 4:00 PM EST
90.06
+0.59 (0.66%)
After-hours: Dec 5, 2025, 7:32 PM EST
Inhibrx Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -155.09 | 1,688 | -241.36 | -115.33 |
| Depreciation & Amortization | 2.61 | 2.29 | 1.19 | 1.23 |
| Other Amortization | 1.8 | 2.07 | 4.9 | - |
| Loss (Gain) From Sale of Assets | 0 | 0.01 | 0 | 0.02 |
| Loss (Gain) on Equity Investments | - | - | 1.63 | - |
| Stock-Based Compensation | 11.38 | 58.52 | 24.85 | 17.79 |
| Other Operating Activities | 1.8 | -1,997 | 0.13 | 1.62 |
| Change in Accounts Receivable | 0.73 | 0.38 | -0.54 | 0.13 |
| Change in Accounts Payable | -5.59 | 17.9 | 2.11 | -0.38 |
| Change in Unearned Revenue | - | - | -0.17 | -1.1 |
| Change in Other Net Operating Assets | -1.03 | 33.77 | 13.94 | 5.21 |
| Operating Cash Flow | -143.39 | -194.41 | -193.31 | -90.81 |
| Capital Expenditures | -0.05 | -2.6 | -4.59 | -0.69 |
| Investing Cash Flow | -0.04 | -2.6 | -4.59 | -0.69 |
| Issuance of Common Stock | 0.35 | 71.68 | 202.32 | - |
| Other Financing Activities | -0.13 | - | -0.36 | 91.5 |
| Financing Cash Flow | 100.19 | 71.68 | 201.96 | 91.5 |
| Net Cash Flow | -43.24 | -125.33 | 4.06 | - |
| Free Cash Flow | -143.44 | -197.01 | -197.9 | -91.5 |
| Free Cash Flow Margin | -10245.64% | -98503.00% | -10994.56% | -6957.95% |
| Free Cash Flow Per Share | -9.27 | -13.15 | -16.80 | -2.12 |
| Cash Interest Paid | 6.39 | 11.51 | 26.72 | - |
| Cash Income Tax Paid | 0 | 0 | 0 | 0 |
| Levered Free Cash Flow | -117.6 | -118.26 | -106.38 | - |
| Unlevered Free Cash Flow | -113.76 | -111.89 | -91.38 | - |
| Change in Working Capital | -5.9 | 52.05 | 15.35 | 3.86 |
Source: S&P Capital IQ. Standard template.
Financial Sources.